Evidence map›Paper›PMID 26344341›Full record

ArticleVaccines2013

DNA-Encoded Flagellin Activates Toll-Like Receptor 5 (TLR5), Nod-like Receptor Family CARD Domain-Containing Protein 4 (NRLC4), and Acts as an Epidermal, Systemic, and Mucosal-Adjuvant.

Sanna Nyström, Andreas Bråve, Tina Falkeborn, Claudia Devito, Björn Rissiek, Daniel X Johansson, Ulf Schröder, Satoshi Uematsu, Shizuo Akira, Jorma Hinkula and 1 more

Open access · goldAbstract read
In one paragraph

Article in Vaccines, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.1field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Inflammasomes as mediators of inflammation in HIV-1 infection.Translational research : the journal of laboratory and clinical medicine · 2023
    Review
  4. Review
  5. Review
  6. Review
  7. Bacterial flagellin-a potent immunomodulatory agent.Experimental & molecular medicine · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 3 countries.

Sanna NyströmCenter for Infectious Medicine, F59, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm 141 86, Sweden.
Andreas BråveDepartment of Preparedness, Swedish Institute for Infectious Disease Control, Stockholm 171 82, Sweden.
Tina FalkebornDivision of Molecular Virology, Department of Clinical and Experimental Medicine, Linköping University, Linköping 581 85, Sweden.
Claudia DevitoDivision of Molecular Virology, Department of Clinical and Experimental Medicine, Linköping University, Linköping 581 85, Sweden.
Björn RissiekCenter for Infectious Medicine, F59, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm 141 86, Sweden.
Daniel X JohanssonDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Nobels väg 16, Stockholm 171 77, Sweden.
Ulf SchröderLatour AB, Stockholm 171 21, Sweden.
Satoshi UematsuDivision of Innate immune regulation, International Research and Development Center for Mucosal Vaccine, Institute for Medical Science, The University of Tokyo, Tokyo 108-8639, Japan.
Shizuo AkiraDepartment of Host of Defense, Research Institutet for Microbial Diseases, Osaka University, Osaka 565-0871, Japan.
Jorma HinkulaDivision of Molecular Virology, Department of Clinical and Experimental Medicine, Linköping University, Linköping 581 85, Sweden.
Steven E ApplequistCenter for Infectious Medicine, F59, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm 141 86, Sweden. steven.applequist@ki.se.
Linköping University · SEKarolinska University Hospital · SEKarolinska Institutet · SELatour (Sweden) · SEOsaka University · JPSwedish Institute · SEThe University of Tokyo · JPUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Eliciting effective immune responses using non-living/replicating DNA vaccines is a significant challenge. We have previously shown that ballistic dermal plasmid DNA-encoded flagellin (FliC) promotes humoral as well as cellular immunity to co-delivered antigens. Here, we observe that a plasmid encoding secreted FliC (pFliC(-gly)) produces flagellin capable of activating two innate immune receptors known to detect flagellin; Toll-like Receptor 5 (TLR5) and Nod-like Receptor family CARD domain-containing protein 4 (NRLC4). To test the ability of pFliC(-gly) to act as an adjuvant we immunized mice with plasmid encoding secreted FliC (pFliC(-gly)) and plasmid encoding a model antigen (ovalbumin) by three different immunization routes representative of dermal, systemic, and mucosal tissues. By all three routes we observed increases in antigen-specific antibodies in serum as well as MHC Class I-dependent cellular immune responses when pFliC(-gly) adjuvant was added. Additionally, we were able to induce mucosal antibody responses and Class II-dependent cellular immune responses after mucosal vaccination with pFliC(-gly). Humoral immune responses elicited by heterologus prime-boost immunization with a plasmid encoding HIV-1 from gp160 followed by protein boosting could be enhanced by use of pFliC(-gly). We also observed enhancement of cross-clade reactive IgA as well as a broadening of B cell epitope reactivity. These observations indicate that plasmid-encoded secreted flagellin can activate multiple innate immune responses and function as an adjuvant to non-living/replicating DNA immunizations. Moreover, the capacity to elicit mucosal immune responses, in addition to dermal and systemic properties, demonstrates the potential of flagellin to be used with vaccines designed to be delivered by various routes.

Indexed as

adaptive immunityDNA adjuvantflagellinNLRC4TLR5

Identifiers

PMID26344341
PMCPMC4494208
OpenAlexW2119900071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.